- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Joey Mattingly, PharmD, MBA
Joey Mattingly, PharmD, MBA, currently serves as an assistant professor in the Department of Pharmacy Practice and Science at the University of Maryland School of Pharmacy, where he teaches business strategy to PharmD students and is a strategic consultant for the University of Maryland Medical Center. In addition to his work as a faculty member, he serves as Director of Operations for the PATIENTS Program and Principal for A & J Consulting, LLC. His primary research interests include cost-effectiveness, patient-centered outcomes, and health policy.
Articles
Pharmacoeconomics Refresher: The CVS $100k/QALY Announcement (Part 3)
December 5th 2018In this series, we have used the recent announcement by CVS Health regarding a strategy to lower drug prices as an example to review basic pharmacoeconomic principles. For Part 3, we are going to discuss various stakeholders and how each might view the results of decisions based off of pharmacoeconomic analyses.
Pharmacoeconomics Refresher: The CVS $100K/QALY Announcement (Part 2)
October 19th 2018This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 2 puts ICER into context so it can be applied to decision-making.
Pharmacoeconomics Refresher: The CVS $100K/QALY Announcement (Part 1)
October 9th 2018This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 1 focuses on definitions and a basic calculation.
